I
n 1979, Lompre et al 1 described the appearance in rat cardiac overload of a V3 myosin isoenzyme with reduced ATPase activity and slower mobility on nondenaturing gels. V3 myosin contains ␤-myosin heavy chain (␤-MyHC), whereas the normal adult V1 myosin with higher ATPase activity contains ␣-MyHC, and protein changes are caused by changes in the mRNAs. [2] [3] [4] In rats and mice, ␤-MyHC mRNA and protein are induced reliably by disease-related hypertrophic stimuli in vivo and by hypertrophic agonists in culture [3] [4] [5] but not by physiological stimuli such as exercise training. 6 Thus, ␤-MyHC has become the classic marker for pathological hypertrophy. Indeed, ␤-MyHC is emblematic of an entire "fetal gene program" that is normally low or absent in adult heart and myocytes and is induced in rodent models of pathological hypertrophy in vivo and in vitro, including skeletal ␣-actin, ␤-tropomyosin, atrial natriuretic factor, and proto-oncogenes such as myc, fos and jun. [7] [8] [9] In the human ventricle, ␤-MyHC and skeletal ␣-actin are predominant normally, 10, 11 but the concept of fetal gene induction in human myocardial disease appears to be valid, as represented by upregulation of atrial natriuretic factor, MB creatine kinase, and atrial ␤-MyHC. [12] [13] [14] If ␤-MyHC is indeed a valid marker for pathological cardiac myocyte hypertrophy, then 2 criteria would appear to follow. First, ␤-MyHC should be induced in most or all myocytes in a hypertrophied heart, and second, the myocytes expressing ␤-MyHC should be hypertrophied, or larger in size. However, a few reports indicate that endogenous ␤-MyHC is expressed heterogeneously in the overloaded myocardium, 15, 16 a mean 30% of myocytes in 1 report, 15 and the same can be true for other fetal genes. 16 -18 The most extensive study used a knock-in reporter mouse with yellow fluorescent protein (YFP) fused to the N-terminus of ␤-MyHC (YFP-␤-MyHC). This approach estimated that myocytes positive for YFP-␤-MyHC constituted 38% of total myocytes after prolonged transverse aortic constriction (TAC); YFP-␤-MyHC-expressing myocytes were found in areas of fibrosis in several hypertrophy models and were hypertrophied to the same extent as myocytes that did not express ␤-MyHC. 19 -22 Here, we sought to simultaneously quantify and size myocytes that expressed endogenous ␤-MyHC protein after TAC using an unbiased approach that did not rely on a genetic marker and that analyzed at least 10 000 cells per heart. To do this, we validated a flow cytometry technique using standard instruments and a commercial monoclonal antibody (mAb) for ␤-MyHC.
Using this approach, we found that ␤-MyHC is induced after TAC in a minor subpopulation of smaller myocytes.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org. Adult male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) age 11 to 12 weeks had TAC by the Rockman method, 23 sufficient to give a gradient after 3 weeks of Ϸ100 mm Hg by Doppler echocardiography. 24 Control animals were sex-and agematched littermates that were sham operated or had no surgery, because these 2 groups had identical ␤-MyHC protein expression.
Adult mouse and rabbit myocytes and nonmyocytes were isolated, by perfusion with collagenase; and fetal and neonatal mouse myocytes by digestion with collagenase. Neonatal rat ventricular myocytes (NRVMs) were isolated with trypsin and cultured in serum-free medium. Isolated cells were fixed in formalin and ethanol for flow cytometry or immunocytochemistry or in formalin for volume assay by a Coulter Multisizer (Beckman Coulter, Brea, CA). Live cells were used in Western blot.
Flow cytometry used 3 different standard benchtop flow cytometers (FACScan, FACSCalibur, and LSRII; BD Biosciences, San Jose, CA) with a 430ϫ180-m flow cell. Fixed cells were permeabilized, blocked, and stained for DNA and with conjugated primary antibodies. Optimal titration of all reagents used the coexisting nonmyocytes in each preparation as the in-tube negative control for myocyte-specific proteins and the positive control for proliferation markers. Preliminary studies defined the antibody dilution that detected the maximum number of cells. At least 10 000 myocytes were assayed in each run, setting positive and negative gates by fluorescence of negative control cells stained with nonspecific mouse IgG. Data were analyzed with FlowJo software on a Mac OSX.
The IgG mAbs included MF-20 mouse anti-sarcomeric MyHC (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA); NOQ7.5.4D mouse anti-␤-MyHC (Sigma-Aldrich, St Louis, MO); 13-11 mouse anti-troponin T (Lab Vision, Fremont, CA); mouse anti-␣-MyHC (clone BA-G5; Abcam, Cambridge, MA); mouse antiKi67 (clone B56; BD Pharmingen, San Diego, CA); and rat anti-CD45 conjugated to allophycocyanin-Cy7 (clone 30-F11; BD Pharmingen). Anti-phospho-histone H3 serine 10 was a rabbit polyclonal IgG (Millipore, Billerica, MA). The mouse mAbs were labeled with Zenon (Invitrogen, Carlsbad, CA) conjugated to Alexa 488 (green), Alexa 546 (orange), Alexa 647 (red), or biotin streptavidin-allophycocyanin-Alexa 780 (far red). For DNA synthesis, a flow cytometry kit quantified incorporation of the thymidine analog ethynyl deoxyuridine.
For immunohistochemistry, the heart was arrested and fixed in diastole so that 7-m frozen sections could be cut.
Results are meanϮSD. Significant differences (PϽ0.05) were tested in GraphPad Prism version 5.0 with 1-way ANOVA and Bonferroni multiple comparison or Newman-Keuls tests for more than 2 groups, or Student's unpaired t test for 2 groups. Linear regression tested for association between cell size by flow cytometry and a Coulter Multisizer.
Results

Flow Cytometry of Isolated Adult Mouse Cardiac Cells
Reliable analysis of myocytes expressing endogenous ␤-MyHC protein required a flow cytometry approach to ϩ cells do not shift on the x-axis, which indicates absence of nonspecific binding of anti-myosin antibody. Right, Myocytes positive for myosin by MF-20 were also positive for troponin T. The 10% contour plots included at least 10 000 to 20 000 nucleated myocytes, and outliers (small dots) represented ϽϷ2% of the cell population. Side scatter (right) is an index of cell size. Cell gates (pink) were set to include Ͻ1% positive cells when cells from the same LV were stained with isotype antibody. B, The fraction of different cell types in the LV was measured 1 to 3 weeks after TAC or sham control (CON Figure 1A illustrates the approach. All small and large cells isolated from mouse left ventricle (LV) were fixed and stained with propidium iodide or 7-amino-actinomycin D for DNA; with anti-CD45 to label white blood cells; and with MF-20 anti-sarcomeric myosin to label all myocytes. An aliquot of cells stained with isotype IgGs was the negative control to set the gates for fluorescent signals. As shown in Figure 1A left, we first eliminated debris by gating on nucleated cells with Ն2N DNA content, then gated nucleated cells for white blood cells, myocytes, and nonmyocytes, the last defined as cells that were negative for both CD45 and MF-20 (Figure 1A middle).
As an additional control for myocyte identification with MF-20, the cells in Figure 1 were also stained with antitroponin T, and all cells positive for MF-20 were also positive for troponin T. In Figure 1A right, troponin reactivity is plotted against side scatter, a flow cytometry index of cell size, which shows the broad size range of these cells.
We tested the flow cytometry approach using cells isolated from the LV at 1 to 3 weeks after TAC or controls. TAC in these experiments was sufficient to cause dilated cardiomyopathy in C57BL/6J mice, 24 with a pressure gradient at 3 weeks of 110Ϯ18 mm Hg (nϭ4; also see Online Figure III ). As shown in Figure 1B , TAC caused a significant decrease in the fraction of LV cells that were myocytes (44Ϯ5% to 26Ϯ2%, PϽ0.01) and an increase in the fraction of white blood cells (5Ϯ1% to 13Ϯ1%, PϽ0.01) and nonmyocytes (52Ϯ5% to 61Ϯ2%, PϽ0.05), as expected from the inflammation and fibrosis in the model. 24, 25 The 40% relative decrease in myocytes as a fraction of total LV cells was a dilution effect caused by more white blood cells and nonmyocytes and was not caused by myocyte loss.
As shown in Figure 1C , TAC did not change the absolute number of myocytes isolated per LV, by hemocytometer counts (in millions: controls 2.1Ϯ0.5, TAC 2.0Ϯ0.6; nϭ63 to 25; Pϭ0. 7) . Approximately 40% of myocytes in both groups were rod-shaped (controls 43Ϯ9% and TAC 40Ϯ13%, Pϭ0.4). Notably, the fraction of myocytes in the mouse LV was lower than estimated by microscopic counts 26 but similar to another flow cytometry analysis. 27 As shown in Figure 2B , the neonatal heart had a higher fraction of myocytes (66%), as has also been observed by others. 27 We concluded that our flow cytometry approach could reproducibly phenotype large and equal numbers of myocytes from the mouse LV, before and after TAC.
Validation of a ␤-MyHC Antibody
We screened 4 commercial mouse mAbs against the ␤ or slow MyHC isoform in striated muscle (NOQ7.5.4D from Sigma, N2.261 and A4.840 from the Developmental Studies Hybridoma Bank, and NCL-MHCs from Novocastra), testing their specificity in identifying cardiac ␤-MyHC. NOQ7.5.4D was the single mAb that satisfied 3 criteria. First, NOQ7.5.4D recognized known developmental and species differences. NOQ7.5.4D recognized that almost all newborn mouse heart myocytes, as defined by MF-20, expressed ␤-MyHC (Figure 2A ), whereas most adult myocytes did not (Figure 3 below) . NOQ7.5.4D also found Ͼ99% ␤-MyHC-positive myocytes in fetal mouse heart and adult rabbit heart (Online Figure II) . Second, NOQ7.5.4D identified downregulation of ␤-MyHC by triiodothyronine in cultured NRVMs, as expected ( Figure 2B ). 28 Third, NOQ7.5.4D identified a band of appropriate size (Ϸ200 kDa) in adult TAC myocytes, by Western blot of 400 myocytes. This band was absent in adult control myocytes ( Figure 3A ). In summary, NQ7.4.5D satisfied 3 criteria for specific recognition of cardiac ␤-MyHC and was used in all subsequent experiments.
␤-MyHC Is Induced in a Minor Subpopulation of LV Myocytes
As shown in Figure 3A , TAC caused a very robust induction of ␤-MyHC when assayed by Western blot of 400 LV myocytes. This finding would typically be interpreted as ␤-MyHC induction in all 400 myocytes. However, Figure 3B shows by immunocytochemistry with the mAb NOQ7.5.4D that ␤-MyHC was present in a minority of myocytes. We used flow cytometry to quantify the fraction of myocytes that expressed ␤-MyHC.
LV myocytes were isolated from control and TAC hearts at 3 weeks; stained with propidium iodide for DNA, CD45 for white blood cells, MF-20 for myocytes, and NOQ7.5.4D for ␤-MyHC; and analyzed by flow cytometry. Figure 3C shows a flow cytometry analysis of the total MF-20-positive myocyte population, similar to the right side of Figure 1A , with ␤-MyHC intensity on the y-axis, and side scatter, a size index, on the x-axis. In this control heart, 3% of total MF-20-positive myocytes were also positive for ␤-MyHC, whereas the TAC heart had 25% of myocytes positive ( Figure 3C ).
To test whether a higher fraction of myocytes expressed ␤-MyHC at times earlier or later than 3 weeks, we isolated LV myocytes from TAC hearts and concurrent sham controls at 3 days to 6 weeks after surgery. Figure 3D shows that the fraction of ␤-MyHC-positive myocytes was increased at 3 days (20Ϯ8%, nϭ5), reached a maximum at 1 week, and was stable for 6 weeks, with overall 25Ϯ10% positive (nϭ24, PϽ0.0001 versus sham; Pϭ0.24 for TAC %␤-MyHC-positive over time). Sham controls hearts had 3Ϯ1% of myocytes positive for ␤-MyHC (nϭ12). The percentage of ␤-MyHC-positive myocytes was the same whether NOQ7.5.4D was labeled with Alexa 488 (green) or Alexa 647 (red; data not shown).
We concluded that endogenous ␤-MyHC was present in 3% of control myocytes and was induced in only 25% of myocytes after TAC.
Validation of Flow Cytometry to Quantify Myocyte Size
We wanted to use flow cytometry to quantify the size of the myocytes that did and did not express ␤-MyHC. The advantage of this strategy compared with microscopic methods would be a much larger sample size. To test whether myocyte side scatter by flow cytometry could be used to quantify size, we compared side scatter with myocyte volume from the Coulter Multisizer, a robust and validated assay. 24, 29 Forward side scatter gave results similar to side scatter (data not shown); however, because the optical geometry of forward scatter varies between instruments, side scatter using a log scale minimized variance from different cytometers, as shown by others. 30 Figure 4A plots volume by Coulter, and side scatter by flow, versus cell number for LV and right ventricular (RV) myocytes from a control heart. Flow correctly identified that LV myocytes were larger than RV myocytes (left panels), and the correlation was excellent between the relative size of LV and RV myocytes detected by flow and by Coulter ( Figure 4A, right) . Similarly, as shown in Figure 4B , side scatter correctly identified the increased size of LV myocytes after TAC (left panels), and the 4D (y-axis) . Percent ␤-MyHC-positive is the fraction positive for NOQ7.5.4D divided by the total MF-20-positive myocytes analyzed. Plots are 10% contours, with dots for outlier myocytes. Positive gates for NOQ7.5.4D were set by isotype staining of myocytes from the same heart (not shown) to include Ͻ1% positive cells above the isotype-stained population, and the same gate was then applied to the sample stained for ␤-MyHC, as illustrated in Figure 1A correlation was excellent between relative size determined by the 2 assays (right panel). The relative size increase was somewhat compressed by the side scatter assay compared with Coulter, which indicates that flow somewhat underestimated the cell size differences (right panels in Figures 4A and 4B) .
We concluded that we could use side scatter by flow cytometry as a surrogate for relative myocyte size.
␤-MyHC-Positive Myocytes Are Smaller
We used side scatter to quantify the relative size of LV myocytes in the same heart that did and did not express ␤-MyHC. Figure  5A presents side scatter versus myocyte number profiles for 3 control and 3 TAC hearts. In each case, ␤-MyHC protein and myocyte size were measured in the same cells from the same LV. Myocytes that express ␤-MyHC were barely detected in control LV but became readily apparent after TAC, and their size was clearly smaller relative to ␤-MyHC-negative myocytes from the same LV ( Figure 5A ).
Figure 5B summarizes the relative size of ␤-MyHC-positive and ␤-MyHC-negative myocytes from 11 control and 14 TAC LVs at 1 to 6 weeks after banding. Mean side scatter for each LV myocyte subpopulation was normalized to the side scatter of the control ␤-MyHC-negative myocytes run in an identical manner on the same cytometer on the same day.
In control LVs, the few ␤-MyHC-positive myocytes (3% of total myocytes) were only 65Ϯ16% as large as the majority of ␤-MyHCnegative myocytes (PϽ0.001; Figure 5B ). In TAC LVs, there were now 25% ␤-MyHC-positive myocytes, and they were only 78Ϯ7% as large as the ␤-MyHC-negative myocytes (PϽ0.001).
Furthermore, the 75% of ␤-MyHC-negative myocytes were the only cells that enlarged after TAC. TAC myocytes negative for ␤-MyHC were 1.28Ϯ0.13-fold larger than the control ␤-MyHC-negative cells (PϽ0.001), equivalent to a 1.59-fold increase in size by cell volume (by extrapolation from the regression equation in the validation experiment; Figure 4B right). ␤-MyHC-negative myocytes enlarged to a plateau over the first week after TAC ( Figure 5C ).
In marked contrast, the 25% of ␤-MyHC-positive myocytes in TAC LVs were the same size as the 97% of ␤-MyHC-negative cells in control hearts (side scatter 1.02Ϯ0.12-fold, Pϭ0.27; volume 1.10-fold by extrapolation from the regression in Figure 4B ). ␤-MyHC-positive myocytes did not enlarge over the entire 6 weeks after TAC ( Figure 5C ). Therefore, ␤-MyHC was induced in smaller myocytes that did not enlarge with TAC.
In summary, LV myocytes that expressed endogenous ␤-MyHC were smaller than myocytes that did not express ␤-MyHC, both before and after TAC. Myocytes without ␤-MyHC, and therefore with ␣-MyHC only, were the myocytes that enlarged with TAC.
␤-MyHC-Positive Myocytes Are in Discrete Regions and Areas of the LV After TAC
We used immunohistochemistry with the mAb NOQ7.5.4D to map the distribution of ␤-MyHC-expressing myocytes after TAC. The 3% of ␤-MyHC-positive cells in control hearts were too few to localize precisely. ␤-MyHC expression after TAC was restricted to the LV, where it was most abundant in the base of the heart, and was less toward the apex, except for a small area of intense expression at the apex (not shown). As shown in Figures 6A and 6B , ␤-MyHC-positive cells in the base of the heart were notable around larger coronary arteries and occurred infrequently in smaller vessels. Isolated clusters of ␤-MyHCpositive cells were also present in the LV septum close to the junction with the RV, as well as near the insertions of the mitral valve leaflets ( Figure 6A ). The tips of the papillary muscles had many ␤-MyHC-positive cells (not shown). Cells stained with the mAb NOQ7.5.4D had clear cross-striations, which confirmed them as myocytes ( Figure 6C ). Prior studies using a reporter gene localized ␤-MyHC induction to areas of fibrosis. 19, 20, 22 To test this localization for endogenous ␤-MyHC, we performed double staining for ␤-MyHC with wheat germ agglutinin to label collagen in fibrotic areas. 24, 31 As shown in Figure 7 , a few myocytes positive for ␤-MyHC were found in sham control hearts ( Figure 7A ). After TAC, cells that expressed ␤-MyHC were observed perivascularly ( Figure 7B ; also seen in Figures 6A  and 6B ), in isolated areas away from vessels or fibrosis ( Figures 7B and 7C) , and in areas of fibrosis ( Figure 7D ). These data showed that cells that expressed endogenous ␤-MyHC after TAC were in discrete regions of the LV and in fibrotic, perivascular, and isolated areas.
␤-MyHC-Positive Myocytes After TAC Arise From Myocytes With ␣-MyHC
To test whether the ␤-MyHC-positive myocytes after TAC arose by proliferation of the preexisting ␤-MyHC cells or some progenitor, we measured by flow cytometry the incorporation of ethynyl deoxyuridine into DNA and cell cycle markers Ki67 and phospho-histone H3. As shown in Online Figure I , these markers were positive in nonmyocytes after TAC but were not positive in myocytes, with or without ␤-MyHC.
Next, we validated an antibody for ␣-MyHC (Online Figure  II) and quantified ␣-MyHC in control and TAC myocytes. As shown in Online Figure III , the relative level of ␣-MyHC per cell, quantified as median fluorescent intensity, was the same in cells with and without ␤-MyHC, before and after TAC. These data indicated that the ␤-MyHC-positive cells arose by new synthesis of ␤-MyHC in cells that already had ␣-MyHC. Importantly, the level of total MyHC, measured with the mAb MF-20, was significantly higher in the ␤-MyHC-positive cells after TAC than in ␤-MyHC-negative cells, which suggests that ␤-MyHC was added to ␣-MyHC, rather than that it replaced ␣-MyHC. Total MyHC in ␤-MyHC-negative cells increased with TAC by 28% versus a 59% increase in cell volume, whereas total MyHC increased by 41% in ␤-MyHC-positive cells that did not enlarge with TAC.
In summary, ␤-MyHC-positive myocytes arose without proliferation or hypertrophy after TAC by new synthesis of ␤-MyHC in ␣-MyHC-containing cells. ␤-MyHC-negative cells after TAC had hypertrophy but a smaller increase in total myosin.
Discussion
The major findings of the present study were as follows: (1 These data challenge the current paradigm of the fetal hypertrophic gene program, showing a fetal gene in nonhypertrophied myocytes and no ␤-MyHC in hypertrophied cells. The data also identify an interesting subpopulation of smaller myocytes that contain ␤-MyHC, ␣-MyHC, and more total MyHC. Figure 8 is a model to summarize the main findings.
Flow cytometry allowed us to quantify ␤-MyHC expression and myocyte size simultaneously in large numbers of myocytes ( Figure 1 ). Our approach is applicable to any standard cytometer, with careful attention to protocol details to avoid instrument clogging. Myocytes were identified by the well-vetted mAb MF-20, and ␤-MyHC-expressing myocytes were defined by a commercial mAb that was selective for ␤-MyHC by several criteria and was used at a dilution maximum for specific detection, in the green or red fluorescent spectra (Figure 2) . We used a model of severe TAC (Ϸ100-mm Hg gradient for 6 weeks) to induce remodeling and recruit the maximum number of ␤-MyHC-positive cells. Equal numbers of LV myocytes were isolated from control and TAC hearts (Ϸ2 million), and 10 000 to 20 000 myocytes were analyzed in each run. Side scatter quantified myocyte size, which was as accurate as a Coulter Multisizer in detecting relative myocyte size differences in validation studies (Figure 4) .
Our estimate of 25% of myocytes expressing ␤-MyHC after TAC for 3 days to 6 weeks ( Figure 3 ) agrees well with 2 earlier studies, although we studied far more hearts (41 versus 6 to 8) and more myocytes per heart (Ͼ10 000 versus 200 to 3000). A mean 30% of rat myocytes were ␤-MyHC-positive at 2 to 14 days after ascending aortic banding, according to counts of 200 isolated cells stained with anti-V3 myosin antibody (mean calculated from Figure 3 in Rappaport et al 15 ) . Similarly, 38% of mouse myocytes had YFP-␤-MyHC at 4 to 8 weeks after TAC, according to imaging of 3000 myocytes in LV sections. 20 Therefore, the present data confirm in a large number of hearts and myocytes that endogenous ␤-MyHC is induced by pressure overload in only a minor subpopulation of LV myocytes.
However, our finding that ␤-MyHC-positive myocytes are smaller disagrees with previous reports that YFP-␤-MyHCpositive and negative myocytes are equally hypertrophied. 19, 21, 22 In contrast, we found that ␤-MyHC-negative cells were the only cells that enlarged with TAC. The difference might be explained by sampling. We quantified size in at least 10 000 myocytes in each of 25 hearts (Figure 5 ), whereas the laboratory of Smithies and colleagues measured cross-sectional area of 100 myocytes in each of 6 hearts. 19, 21, 22 Alternatively, the YFP-␤-MyHC fusion protein might itself have induced myocyte hypertrophy, 32 whereas we studied endogenous ␤-MyHC.
An intriguing observation here was that the few ␤-MyHCexpressing myocytes were reproducibly present in discrete LV regions, including the LV-RV junction at the base, the insertion points of the mitral valve, the papillary muscles, and the apex ( Figure 6 ). This regional distribution is extremely similar to that seen in 5-to 9-month-old FVB/N mice. 33 We also found ␤-MyHC-positive cells around larger coronaries, similar to atrial natriuretic factor. 34 Besides perivascular locations, ␤-MyHC myocytes were in areas of fibrosis and in isolated areas away from vessels or fibrosis (Figure 7) . In this respect, induction of endogenous ␤-MyHC protein was not limited to areas of fibrosis, unlike the YFP-␤-MyHC fusion protein. 19, 22 It is unknown what might determine the localization of ␤-MyHC cells, but there is an intriguing overlap with a stem cell niche in the apex, 35 and atrial natriuretic factor and skeletal ␣-actin can also be found in fibrotic areas. 17, 18 We have shown that the ␤-MyHC-positive myocytes arise without proliferation or hypertrophy by new synthesis of ␤-MyHC in cells with ␣-MyHC. There was no isoform "switch." Coexpression of ␣-MyHC in ␤-MyHC cells was noted in previous studies. 15, 36, 37 However, because all neonatal myocytes can express ␤-MyHC (Figure 2) , it is unknown why only a subpopulation of smaller adult myocytes in discrete LV regions retains the ability to transcribe ␤-MyHC with the stress of TAC. Also unknown is what else might distinguish the ␤-MyHC cells. For example, we have been unable to validate suitable antibodies for other fetal genes, such as atrial natriuretic factor. The small ␤-MyHC cells might be related to the small mononuclear, high-functioning myocytes identified in the cat and mouse heart, 38,39 although we could not measure nuclear number reliably in the ␤-MyHC cells. In any case, the ␤-MyHC myocytes must uniquely have signaling molecules that can activate ␤-MyHC transcription with stress. One candidate is ␣1-adrenergic receptors, which induce ␤-MyHC 4, 24, 40 and are also expressed in a subpopulation of myocytes. 41 The present findings have important implications for the study of hypertrophic signaling. First and most obviously, ␤-MyHC induction does not indicate myocyte hypertrophy. Myocytes with ␣-MyHC but not ␤-MyHC are the predominant population with hypertrophy after TAC. Therefore, signaling schemes focused on ␤-MyHC transcription might not be relevant to most myocytes ( Figure 8 ). ␤-MyHC transcription is a poor marker for "hypertrophic signaling." Second, the data caution against genetic approaches that test the functional role of ␤-MyHC by placing ␤-MyHC in most or all myocytes, such as adenovirus or transgenesis with the ␣-MyHC promoter. 42, 43 It is controversial whether ␤-MyHC induction and the fetal program are maladaptive 11, 44 or adaptive, [45] [46] [47] and reliable induction as a function of disease severity does not answer this question. Transgenic models show that even high-level replacement of ␣-MyHC with ␤-MyHC causes no or mild pathology 42, 43, 48, 49 or can be beneficial. 50, 51 In the present experiments, the ␤-MyHC cells with more total MyHC did not have hypertrophy, whereas the cells with only ␣-MyHC did. ␤-MyHC In control C57BL/6J male mouse hearts, 97% of myocytes had ␣-MyHC protein only (green), and 3% of myocytes coexpressed both ␤-MyHC (red) and ␣-MyHC proteins. After TAC, 25% of myocytes were positive for both ␤-MyHC and ␣-MyHC, which suggests that the ␤-MyHC cells arose by new synthesis of ␤-MyHC in ␣-MyHC-containing myocytes. Myocytes with ␤-MyHC were significantly smaller than myocytes with ␣-MyHC only, both before and after TAC. The hypertrophied myocytes after TAC expressed only ␣-MyHC, and the amount of ␣-MyHC per myocyte did not appear to increase as much as did cell size. ␤-MyHC cells had significantly more total MyHC. might be antihypertrophic; for example, replacing ␣-MyHC with ␤-MyHC causes less hypertrophy in a troponin T mutant mouse. 51 Increasing myocyte total MyHC and myofibrils causes improved function, 52, 53 whereas loss of myosin and myofibrils causes worse function in human cardiomyopathy and in an ␣1-adrenergic receptor knockout model in which ␤-MyHC and other fetal genes are not induced. 24, 54 Possibly, the ␤-MyHC-positive myocytes have a larger volume fraction of myofibrils, better function, and no deleterious secondary hypertrophy.
In summary, we used flow cytometry to show that ␤-MyHC is induced by pressure overload in only a minor subpopulation of smaller cardiac myocytes. These data challenge the current paradigm of the fetal hypertrophic gene program and identify a new subpopulation of smaller working ventricular myocytes with more myosin.
What New Information Does This Article Contribute?
• Endogenous ␤-MyHC protein is induced by pressure overload in only a small subpopulation of mouse cardiac myocytes.
• Pressure-overloaded myocytes with ␤-MyHC are not hypertrophied and are smaller than myocytes that have only ␣-MyHC, the normal adult MyHC isoform.
• Myocytes with ␤-MyHC arise without proliferation or hypertrophy by adding ␤-MyHC to ␣-MyHC, and they have more total MyHC per cell than the hypertrophied myocytes with only ␣-MyHC.
␤-MyHC in rodent cardiac myocytes is expressed normally during fetal development and is replaced by ␣-MyHC after birth.
It is induced robustly in the adult heart with pressure overload and other cardiac diseases. ␤-MyHC induction has therefore become a classic marker for pathological hypertrophy, but the functional significance of ␤-MyHC induction remains controversial. Here, we used flow cytometry to quantify the number and size of mouse cardiac myocytes that expressed ␤-MyHC after pressure overload caused by transverse aortic constriction. We found that ␤-MyHC is induced in a minor subpopulation of smaller myocytes that have more total MyHC. Surprisingly, myocytes with only ␣-MyHC accounted for hypertrophy after pressure overload, but these ␣-MyHC myocytes had relatively less MyHC per cell, a potentially maladaptive phenotype. These data challenge the current paradigm of the fetal hypertrophic gene program by showing the fetal gene ␤-MyHC in nonhypertrophied myocytes and no ␤-MyHC in hypertrophied cells. The data also identify an interesting subpopulation of smaller myocytes that contain ␣-MyHC plus ␤-MyHC, as well as more total MyHC. This subpopulation of myocytes might represent an adaptive mechanism, which could be amplified in the stressed myocardium as a novel therapeutic target.
